- Home
- GH vs ACLX Comparison
GH vs ACLX Comparison
Compare GH & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | ACLX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GH | ACLX |
|---|---|---|
| Price | $103.60 | $68.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | $79.19 | ★ $115.50 |
| AVG Volume (30 Days) | ★ 2.9M | 920.2K |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $902,569,000.00 | $35,898,000.00 |
| Revenue This Year | $34.72 | N/A |
| Revenue Next Year | $26.46 | $220.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.38 | N/A |
| 52 Week Low | $29.91 | $47.86 |
| 52 Week High | $112.43 | $96.39 |
Technical Indicators
Market Signals| Indicator | GH | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 25.98 |
| Support Level | $98.23 | $71.05 |
| Resistance Level | $112.43 | $74.00 |
| Average True Range (ATR) | 5.44 | 4.75 |
| MACD | -0.54 | -2.34 |
| Stochastic Oscillator | 64.46 | 4.59 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.